Cargando…

Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax

Detalles Bibliográficos
Autores principales: Izutsu, Koji, Yamamoto, Kazuhito, Kato, Koji, Ishikawa, Takayuki, Fukuhara, Noriko, Terui, Yasuhito, Choi, Ilseung, Okubo, Sumiko, Ogawa, Natsumi, Sakai, Mizu, Nishimura, Yasuko, Chyla, Brenda, Sun, Yan, Maruyama, Dai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522736/
https://www.ncbi.nlm.nih.gov/pubmed/37581752
http://dx.doi.org/10.1007/s12185-023-03646-3
_version_ 1785110417663590400
author Izutsu, Koji
Yamamoto, Kazuhito
Kato, Koji
Ishikawa, Takayuki
Fukuhara, Noriko
Terui, Yasuhito
Choi, Ilseung
Okubo, Sumiko
Ogawa, Natsumi
Sakai, Mizu
Nishimura, Yasuko
Chyla, Brenda
Sun, Yan
Maruyama, Dai
author_facet Izutsu, Koji
Yamamoto, Kazuhito
Kato, Koji
Ishikawa, Takayuki
Fukuhara, Noriko
Terui, Yasuhito
Choi, Ilseung
Okubo, Sumiko
Ogawa, Natsumi
Sakai, Mizu
Nishimura, Yasuko
Chyla, Brenda
Sun, Yan
Maruyama, Dai
author_sort Izutsu, Koji
collection PubMed
description
format Online
Article
Text
id pubmed-10522736
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-105227362023-09-28 Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax Izutsu, Koji Yamamoto, Kazuhito Kato, Koji Ishikawa, Takayuki Fukuhara, Noriko Terui, Yasuhito Choi, Ilseung Okubo, Sumiko Ogawa, Natsumi Sakai, Mizu Nishimura, Yasuko Chyla, Brenda Sun, Yan Maruyama, Dai Int J Hematol Letter to the Editor Springer Nature Singapore 2023-08-15 2023 /pmc/articles/PMC10522736/ /pubmed/37581752 http://dx.doi.org/10.1007/s12185-023-03646-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Letter to the Editor
Izutsu, Koji
Yamamoto, Kazuhito
Kato, Koji
Ishikawa, Takayuki
Fukuhara, Noriko
Terui, Yasuhito
Choi, Ilseung
Okubo, Sumiko
Ogawa, Natsumi
Sakai, Mizu
Nishimura, Yasuko
Chyla, Brenda
Sun, Yan
Maruyama, Dai
Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
title Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
title_full Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
title_fullStr Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
title_full_unstemmed Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
title_short Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
title_sort measurable residual disease in japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522736/
https://www.ncbi.nlm.nih.gov/pubmed/37581752
http://dx.doi.org/10.1007/s12185-023-03646-3
work_keys_str_mv AT izutsukoji measurableresidualdiseaseinjapanesepatientswithrelapsedorrefractorychroniclymphocyticleukemiatreatedwithvenetoclax
AT yamamotokazuhito measurableresidualdiseaseinjapanesepatientswithrelapsedorrefractorychroniclymphocyticleukemiatreatedwithvenetoclax
AT katokoji measurableresidualdiseaseinjapanesepatientswithrelapsedorrefractorychroniclymphocyticleukemiatreatedwithvenetoclax
AT ishikawatakayuki measurableresidualdiseaseinjapanesepatientswithrelapsedorrefractorychroniclymphocyticleukemiatreatedwithvenetoclax
AT fukuharanoriko measurableresidualdiseaseinjapanesepatientswithrelapsedorrefractorychroniclymphocyticleukemiatreatedwithvenetoclax
AT teruiyasuhito measurableresidualdiseaseinjapanesepatientswithrelapsedorrefractorychroniclymphocyticleukemiatreatedwithvenetoclax
AT choiilseung measurableresidualdiseaseinjapanesepatientswithrelapsedorrefractorychroniclymphocyticleukemiatreatedwithvenetoclax
AT okubosumiko measurableresidualdiseaseinjapanesepatientswithrelapsedorrefractorychroniclymphocyticleukemiatreatedwithvenetoclax
AT ogawanatsumi measurableresidualdiseaseinjapanesepatientswithrelapsedorrefractorychroniclymphocyticleukemiatreatedwithvenetoclax
AT sakaimizu measurableresidualdiseaseinjapanesepatientswithrelapsedorrefractorychroniclymphocyticleukemiatreatedwithvenetoclax
AT nishimurayasuko measurableresidualdiseaseinjapanesepatientswithrelapsedorrefractorychroniclymphocyticleukemiatreatedwithvenetoclax
AT chylabrenda measurableresidualdiseaseinjapanesepatientswithrelapsedorrefractorychroniclymphocyticleukemiatreatedwithvenetoclax
AT sunyan measurableresidualdiseaseinjapanesepatientswithrelapsedorrefractorychroniclymphocyticleukemiatreatedwithvenetoclax
AT maruyamadai measurableresidualdiseaseinjapanesepatientswithrelapsedorrefractorychroniclymphocyticleukemiatreatedwithvenetoclax